Reduction-Responsive Cationic Vesicles from Bolaamphiphiles with Ionizable Amino Acid or Dipeptide Polar Heads.
Journal
Langmuir : the ACS journal of surfaces and colloids
ISSN: 1520-5827
Titre abrégé: Langmuir
Pays: United States
ID NLM: 9882736
Informations de publication
Date de publication:
03 10 2023
03 10 2023
Historique:
medline:
4
10
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
ppublish
Résumé
This paper presents a study of the aggregation of cationic bolaamphiphilic molecules into vesicles. These molecules are based on a cystamine core with protonated terminal dipeptide groups. The study found that vesicles can be formed at pH 4 for all of the dipeptide-terminated bolaamphiphiles containing different combinations of l-valine, l-phenylalanine, and l-tryptophan. The concentration for aggregation onset was determined by using pyrene as a fluorescent probe or light dispersion for compounds with tryptophan. Dynamic light scattering (DLS) studies and transmission electron microscopy (TEM) reveal that the vesicles have diameters ranging from 140 to 500 nm and show the capability of loading hydrophobic cargos, such as Nile red, and their liberation in reductive environments. Furthermore, the bolaamphiphiles are only fully protonated and prone to vesicle formation at acidic pH, making them a promising alternative for gastrointestinal delivery.
Identifiants
pubmed: 37729523
doi: 10.1021/acs.langmuir.3c01294
pmc: PMC10552552
doi:
Substances chimiques
Amino Acids
0
bolaamphiphile
0
Dipeptides
0
Furans
0
Pyridones
0
Tryptophan
8DUH1N11BX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13841-13849Références
J Control Release. 2001 Aug 10;75(3):401-8
pubmed: 11489326
Drug Discov Today. 2021 Aug;26(8):1794-1824
pubmed: 34058372
Eur J Pharm Biopharm. 2021 Aug;165:279-292
pubmed: 34033881
ACS Appl Bio Mater. 2021 Jul 19;4(7):5717-5726
pubmed: 35006755
Drug Deliv Transl Res. 2014 Feb;4(1):96-103
pubmed: 25786620
Angew Chem Int Ed Engl. 2014 Nov 24;53(48):13126-30
pubmed: 25267331
ACS Omega. 2020 Jun 30;5(27):16701-16710
pubmed: 32685837
Langmuir. 1985 May;1(3):352-5
pubmed: 21370917
Nat Commun. 2019 Sep 24;10(1):4333
pubmed: 31551417
J Control Release. 2016 Aug 10;235:99-111
pubmed: 27242198
Langmuir. 2009 Aug 18;25(16):9447-53
pubmed: 19537819
Biochemistry. 1988 May 31;27(11):3917-25
pubmed: 3415963
Langmuir. 2012 Sep 25;28(38):13668-74
pubmed: 22931455
Chem Rev. 2021 Oct 27;121(20):12181-12277
pubmed: 34279087
Pharmaceuticals (Basel). 2022 Jun 18;15(6):
pubmed: 35745680
Colloids Surf B Biointerfaces. 2009 Feb 1;68(2):136-44
pubmed: 18993036
Biomater Adv. 2022 Aug;139:212984
pubmed: 35882140
J Colloid Interface Sci. 2010 Oct 1;350(1):10-5
pubmed: 20638071
Nat Biotechnol. 2010 Feb;28(2):172-6
pubmed: 20081866
Chem Rev. 2004 Jun;104(6):2901-37
pubmed: 15186184
J Colloid Interface Sci. 2014 Dec 15;436:138-45
pubmed: 25268817
J Biotechnol. 2007 May 31;130(1):85-94
pubmed: 17442442
Phys Biol. 2006 Feb 02;3(1):S10-9
pubmed: 16582461
ACS Appl Bio Mater. 2021 Sep 20;4(9):7111-7122
pubmed: 35006943
J Liposome Res. 2010 Jun;20(2):147-59
pubmed: 19848552
Colloids Surf B Biointerfaces. 2016 May 1;141:19-27
pubmed: 26820106
Pharm Res. 1998 Feb;15(2):334-7
pubmed: 9523323
Biochim Biophys Acta. 2014 Oct;1838(10):2646-55
pubmed: 25017801
Nat Chem. 2021 Nov;13(11):1046-1054
pubmed: 34645986
Langmuir. 2015 Mar 10;31(9):2639-48
pubmed: 25671716
Drug Deliv. 2004 Mar-Apr;11(2):123-8
pubmed: 15200011
Chem Phys Lipids. 2006 Apr;140(1-2):66-74
pubmed: 16494856
Int J Nanomedicine. 2016 Aug 01;11:3607-19
pubmed: 27536102
J Control Release. 2021 Apr 10;332:269-284
pubmed: 33662455
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):381-9
pubmed: 23791683
Chem Phys Lipids. 2004 Sep;131(2):197-204
pubmed: 15351271
Eur J Biochem. 1995 Mar 15;228(3):697-703
pubmed: 7737166
Int J Pharm. 2017 Aug 30;529(1-2):245-252
pubmed: 28668583
Langmuir. 2013 Jun 4;29(22):6519-28
pubmed: 23647396